Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26690667 | 1.00 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3JAK3 | |
| SCHEMBL447190 | 1.00 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3JAK3 | |
| Hydrochloric Acid SCHEMBL29908691 | 0.98 | HTR3A (0.96) | HTR3ASLC6A2SLC6A3JAK3 | |
| Hydrochloric Acid SCHEMBL4573036 | 0.98 | HTR3A (0.96) | HTR3ASLC6A2SLC6A3JAK3 | |
| SCHEMBL308190 | 0.90 | HTR3A (0.81) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL16446546 | 0.90 | HTR3A (0.81) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL16446343 | 0.90 | HTR3A (0.81) | HTR3ASLC6A2SLC6A3 | |
| Oxalic Acid SCHEMBL3546578 | 0.89 | HTR3A (0.80) | HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL2884603 | 0.88 | HTR3A (0.79) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL187003 | 0.87 | HTR3A (0.77) | HTR3ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635494-A2 | AMIDO HETEROAROMATIC COMPOUNDS | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4514782-B1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-12291524-B2 | Amido heteroaromatic compounds | ASTRAZENECA AB (SE) | 2025-05-06 | — | — | US | disclosed |
| EP-4514782-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2025-01-09 | — | — | US | disclosed |
| CN-119173506-A | Amide heteroaromatic compounds for the treatment of liver diseases | 阿斯利康(瑞典)有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2023222850-A1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| CN-111936488-B | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3743419-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| CN-111936488-A | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019145360-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019145360-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291524-B2 | Amido heteroaromatic compounds | CYP7A1, SLC10A1, CYP11B2 | HTR3A 1944/4885SLC6A2 1160/4885SLC6A3 2143/4885 |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | PIGO, ENPP2, THPO | HTR3A 4719/4885SLC6A2 2997/4885SLC6A3 3645/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | HTR3A 1944/4885SLC6A2 1160/4885SLC6A3 2143/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | HTR3A 4363/4885SLC6A2 4224/4885SLC6A3 4773/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | HTR3A 4363/4885SLC6A2 4224/4885SLC6A3 4773/4885 |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | HTR3A 1944/4885SLC6A2 1160/4885SLC6A3 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.